New combo shows promise in tough lung cancer

NCT ID NCT04702880

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times

Summary

This study tested whether adding an experimental drug (BMS-986012) to standard chemotherapy and immunotherapy could help people with advanced small cell lung cancer live longer without their cancer growing. About 135 newly diagnosed patients took part. The goal was to see if the new combination was safe and worked better than the standard treatment alone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution

Cincinnati, Ohio, 45267, United States
Local Institution

Dallas, Texas, 75390, United States
Local Institution - 0001

Malvern, Victoria, 3144, Australia
Local Institution - 0002

Durham, North Carolina, 27710, United States
Local Institution - 0003

Westmead, New South Wales, 2145, Australia
Local Institution - 0004

Murdoch, Western Australia, 6150, Australia
Local Institution - 0005

Majadahonda, 28222, Spain
Local Institution - 0006

Málaga, 29010, Spain
Local Institution - 0007

Barcelona, Barcelona [Barcelona], 08035, Spain
Local Institution - 0012

Edmonton, Alberta, T6G 1Z2, Canada
Local Institution - 0021

Madrid, 28041, Spain
Local Institution - 0022

Hackensack, New Jersey, 07601, United States
Local Institution - 0023

Greenslopes, Queensland, 4120, Australia
Local Institution - 0029

Rozzano, 20089, Italy
Local Institution - 0030

Peschiera del Garda, 37019, Italy
Local Institution - 0031

Pisa, 56124, Italy
Local Institution - 0034

Ghent, 9000, Belgium
Local Institution - 0036

Athens, 11527, Greece
Local Institution - 0038

Athens, 185 47, Greece
Local Institution - 0039

Amsterdam, North Holland, 1081 HV, Netherlands
Local Institution - 0040

Groningen, 9700RB, Netherlands
Local Institution - 0041

Craiova, 200542, Romania
Local Institution - 0042

Cluj-Napoca, 400015, Romania
Local Institution - 0043

Bucharest, 022328, Romania
Local Institution - 0045

Heraklion, Irakleío, 715 00, Greece
Local Institution - 0048

Lodz, 93-338, Poland
Local Institution - 0049

Gdansk, 80-214, Poland
Local Institution - 0050

Liège, 4000, Belgium
Local Institution - 0051

Charleroi, Hainaut, 6060, Belgium
Local Institution - 0060

Cincinnati, Ohio, 45267, United States
Local Institution - 0064

Brampton, Ontario, L6R 3J7, Canada
Local Institution - 0066

Arnhem, 6815 AD, Netherlands
Local Institution - 0067

Cleveland, Ohio, 44106-1716, United States
Local Institution - 0069

Takatsuki, Osaka, 5698686, Japan
Local Institution - 0070

Ōsaka-sayama, Osaka, 589-8511, Japan
Local Institution - 0073

Sendai, Miyagi, 980-0873, Japan
Local Institution - 0075

Birmingham, Alabama, 35249, United States
Local Institution - 0077

Ina-machi, Saitama, 362-0806, Japan
Local Institution - 0081

Nashville, Tennessee, 37203, United States

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER EXTENSIVE-STAGE SMALL-CELL LUNG CANCER